Major Collaborative Research Agreements in Effect in Fiscal Year 2007
NIAID Technology Transfer Activities
Technology Transfer Highlights
CRADAs
MCRADAs
RCAs
Conditional Gift Acceptance Letters
CTAs
NIAID Technology Transfer Activities
| Fiscal Year |
Pending US Pat. Appls. |
Issued US Patents |
Licenses In Effect |
Active CRADAs |
| 1998 |
158 |
128 |
119 |
95 |
| 1999 |
162 |
148 |
145 |
74 |
| 2000 |
171 |
161 |
138 |
86 |
| 2001 |
167 |
174 |
147 |
93 |
| 2002 |
188 |
187 |
157 |
85 |
| 2003 |
207 |
189 |
153 |
71 |
| 2004 |
221 |
203 |
142 |
70 |
| 2005 |
234 |
207 |
159 |
76 |
| 2006 |
229 |
214 |
154 |
73 |
| 2007 |
244 |
227 |
148 |
60 |
back to top
Technology Tranfer Highlights
In FY 2007, NIAID participated in and OTD negotiated or facilitated, the following partnership agreements:
CRADAs
| Division |
Collaborator |
PI |
Title |
| DCR |
Omrix |
Lane |
The Development of Passive Immunotherapy Product(s) Against Influenza |
| DIR |
AlphaVax |
Cohen |
Pre-Clinical Evaluation of Alphavaccine vectors against rhesus lymphocryptovirus as a model for a prophylactic human vaccine against Epstein-Barr virus (EBV) |
| DIR |
Wellstat Diagnostics |
Lenardo |
Development of novel diagnostic assays for early detection and monitoring of infectious and immune disorders in humans using a proprietary electrochemiluminescense (“ECL”) technology |
| DIR |
Wellstat Diagnostics |
Lenardo |
Development of novel tolerogen therapeutics for human immune disease processes |
| DMID |
GlaxoSmithKline |
Deal |
Amendment #2 to CRADA –A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy of rgD/Alum/MPL vaccine in the prevention of genital herpes disease in young sexually active women (DMID#01-643) |
| VRC |
GenVec |
Graham |
Evaluation of Adenoviral Vectors Encoding Surface Glycoproteins from Respiratory Syncytial Virus |
| VRC |
ImmuRx |
Seder |
Induction of Broad-Based Immunity Following Vaccination with Protein, CD40 Agonists and Toll-like Receptor Ligands or Type 1 Interferon |
back to top
MCRADAs
| Division |
Collaborator |
PI |
Title |
| DIR |
Antigenics |
Farber |
Immunogenicty studies with vaccinia, HIV/SIV, and SARS antigens in combination with Antigenics' proprietary QS21 adjuvant |
| DIR |
Centocor |
Strober |
The role of Interleukin-12 Family Cytokines in Trinitrobenzene sulphonic acid (TNBS)-Colitis, Oxazolone Colitis and Other Experimental Colitides |
| DIR |
Domantis Ltd |
Subbarao |
Effect of Monoclonal antibody to Interferon Gamma on H5N1 isolates of Influenza type-A |
| DIR |
Wyeth-Ayerst |
Wynn |
The elucidation of the role of interleukin-22 (IL-22) in modulating immune responses after pathogen challenges |
| VRC |
Crucell Holland, B.V. |
Koup |
Continuing Studies to Screen Potential Vaccine Recipients for the Presence and Levels of Neutralizing Antibodies Against Ad5, Ad11, Ad35, Ad49 and Ad5.HVR48 Adenoviral Vectors |
| VRC |
GSK |
Douek |
Treatment of Simian Immunodeficiency Virus (SIV)–infected rhesus macaques with CRX-526, a Toll-Like Receptor 4 (TLR4) Antagonist |
back to top
RCAs
| Division |
Collaborator |
PI |
Title |
| DIR |
Bar Harbor BioTechnology |
Morse |
Alpha-Testing of ImmunoQuant Arrays Prototypes by Assessing Gene expression Profiles |
| DIR |
Duke University |
Connors |
Explore whether the HCP5 or HLA-C polymorphisms have an effect on viral load that is independent of the effects of HLA B57 |
| DIR |
International Livestock Research Institute |
Ribeiro |
Comparative EST Sequencing of Infected Tick Salivary Gland Tissue |
| DIR |
National Center for Parasitology, Entomology and Malaria Control (CNM), Ministry of Health of the Kingdom of Cambodia |
Gwadz |
Association of Genetic Polymorphism and Malaria in Cambodians |
| DIR |
Novartis Inst. for Tropical Diseases |
Barry |
Drug development for chronic tuberculosis |
| DIR |
PanThera Biopharma, LLC |
Leppla |
Characterization of Specific Anthrax Lethal Factor Inhibitors |
| DIR |
Promedior Inc. |
Wynn |
Characterization of hSAP's role in fibrosis development and the immune response to schistosome infection |
| DIR |
Trellis Bioscience |
Pierce |
Study of memory B cells specific for malaria parasite, P. falciparum |
| DIR |
Tropical Medicine Institute |
Gwadz |
Malarial Parasite Diversity and Drug Resistance |
| DIR |
Walter Reed Army Institute of Research |
Long |
Optimization of in vitro assys for immunogenicity testing of malaria vaccine candidates |
| VRC |
BioDelivery Sciences International Inc. |
Graham |
Improved Immunogenicity of the RSV when Formulated in Cochleates |
| VRC |
Bioject |
Graham |
The use of Needle-free Injection System in DNA Influenza Vaccine Study (Protocol#305) |
| VRC |
Children's Hosp. of Philadelphia |
Graham |
Evaluation of Adeno-Associated Virus (AAV) Vector Technology as a Method for Vaccination against RSV |
| VRC |
Columbia University |
Sullivan |
Generation of Ebola antigen-specific monoclonal antibodies from B-cells of vaccinated macaques |
| VRC |
Inst. for Research in Biomedicine |
Sullivan |
Generation of human Mabs reactive to Ebola GP |
| VRC |
Merck |
Gomez |
Merck know-how on large scale vaccine production |
| VRC |
Merck |
Wyatt |
Amendment #1 - HIV Neutralizing Antibody Responses When Formulated in Lipophilic System |
| VRC |
Schrodinger |
Kwong |
In Silico Model of gp120-CCR5-N terminus |
| VRC |
University of Geneva |
Nabel |
Generation of human Mabs reactive to Ebola GP |
| VRC |
University of Medicine & Dentistry of New Jersey |
Wyatt |
The Effect of Mutations Introduced into HIV-1 Env on Neutralizing Activity of Ser |
back to top
Conditional Gift Acceptance Letters
| Division |
Collaborator |
PI |
Title |
| DIR |
Canadian Institute for Advanced Research |
Grigg |
CIFAR Program in Integrated Microbial Diversity |
| DIR |
Fraunhofer USA CMB |
Miller |
Development of the Transmission Blocking Vaccine |
| DIR |
PATH |
Long |
Malaria in vitro growth inhibition assays |
| VRC |
Beth Israel Deaconess Medical Center |
Nabel |
Novel Recombinant Adenovirus, Plasmid DNA and Mycobacteria Vector Based Vaccines for HIV-1 |
| VRC |
Duke University Medical Center/Gates |
Mascola |
Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC) |
| VRC |
FNIH/Gates |
Koup |
Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) |
| VRC |
IAVI/Gates |
Koup |
Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) |
| VRC |
UAB/Gates |
Kwong Wyatt |
Amendment #4 - Molecular Analysis and Modeling of HIV-1 Transmission, Containment and Escape |
back to top
CTAs
| Division |
Collaborator |
PI |
Title |
| DAIDS |
Tibotec |
|
The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen |
| DIR |
Human Genome Sciences |
Kottilil |
An open label non-randomized trial to assess safety and tolerability of albumin interferon alpha-2b 1200 mcg and 1800 mcg every two weeks with ribavirin among HIV’HCV coinfected individuals |
| DIR |
PATH |
Miller |
Phase 1 Study of the Safety, Reactogenicity and Immunigenicity of AMA1C/ISA720 |
| DIR |
Takeda Pharmaceuticals North America |
Hadigan |
|
| DIR |
Tercica |
Malech |
Treatment for Growth Failure in Patients with X-linked Severe Combined Immunodeficiency (XSCID): A Phase II Study Assessing Safety and Clinical Response to Treatment with IGF-1 |
| DMID |
Emergent Product Development UK |
Rubin |
A phase 1 open-label dose-escalation single center study to evaluate the safety, tolerability and immunogenicity of a single-component and two-component protein GBS vaccine administrered to adults on three occasions each 28 days apart |
| DMID |
Hoffman-La Roche Ltd |
|
A Phase III, Randomized, Placebo-Controlled, Blinded Investigation of Six Weeks Vs. Six Months of oral Valganciclovir Therapy in Infants with Symptomatic Congenital Cytomegalovirus infection (CASG 112) |
| DMID |
Joint Vaccine Acquisition Program (JVAP) of Chemical Biological Medical Systems |
|
DMID Protocol 01-003: “Phase 1 Trial of the Safety and Immunogenicity of the rPA from Baccilus anthracis [Delta Sterne-1 (pPA102) CR4 Strain] Vaccine Anthrax |
| DMID |
Sanofi-Pasteur, Inc. |
Rubin |
Safety and Immunogenicity of DTaP Vaccine in Healthy Pregnant Women, Safety in their Neonates, and Effect of Maternal Immmunization on Infant Immune Responses to DTaP Vaccine |
| VRC/DAIDS |
IAVI |
|
IAVI Protocol V002 “A Phase 2, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine in Healthy Adult Volunteers at Risk for HIV Infection |
| VRC/DAIDS |
IAVI |
|
(IAVI/PAVE 100) A Phase IIB Test-of-Concept, Randomized, Double-Blinded, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV-Uninfected Persons |
| VRC/DAIDS |
Merck & Co., Inc. |
|
HVTN protocol #071 “A Phase I B clinical trial to define assays and methods to be used for evaluating potential correlates of immunity following administration of the Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in healthy, HIV-1 uninfected adult participants |
back to top